Cell cycle control as a promising target in melanoma

Current Opinion in Oncology

Volumn 27, Issue 2, 2015, Pages 141-150

  Lee, Belinda ^a   Sandhu, Shahneen ^a   McArthur, Grant ^a,b,c  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c Oncogenic Signalling and Growth Control Program   (Australia)

Author keywords

CDK; Cell cycle control; MDM2; Melanoma; p53

Indexed keywords

ABEMACICLIB; CYCLIN D; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR 2A; PALBOCICLIB; PROTEIN MDM2; PROTEIN MDMX; PROTEIN P53; RETINOBLASTOMA PROTEIN; RIBOCICLIB; CARRIER PROTEIN;

ARTICLE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CELL CYCLE CHECKPOINT; CELL CYCLE REGULATION; ENZYME INHIBITION; HUMAN; MELANOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN TARGETING; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIGNAL TRANSDUCTION; SKIN CARCINOGENESIS; VIRUS ONCOGENE; ANTAGONISTS AND INHIBITORS; CELL CYCLE; CELL TRANSFORMATION; DISEASE COURSE; DRUG EFFECTS; GENETICS;

CARRIER PROTEINS; CELL CYCLE; CELL TRANSFORMATION, NEOPLASTIC; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DISEASE PROGRESSION; HUMANS; MELANOMA; SIGNAL TRANSDUCTION;

EID: 84922662201     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0000000000000159     Document Type: Article

References (50)

1. Beroukhim R, Mermel CH, Porter D, et al. The landscape of somatic copy-number alteration across human cancers. Nature 2010; 463:899-905.
2. Lade-Keller J, Riber-Hansen R, Guldberg P, et al. Immunohistochemical analysis of molecular drivers in melanoma identifies p16 as an independent prognostic biomarker. J Clin Pathol 2014; 67:520-528.
3. Potrony M, Puig-Butillé JA, Aguilera P, et al. Increased prevalence of lung, breast, and pancreatic cancers in addition to melanoma risk in families bearing the cyclin-dependent kinase inhibitor 2A mutation: Implications for genetic counseling. J Am Acad Dermatol 2014.
4. Young RJ, Waldeck K, Martin C, et al. Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines. Pigment Cell Melanoma Res 2014; 27:590-600.
5. Hodis E, Watson IR, Kryukov GV, et al. A landscape of driver mutations in melanoma. Cell 2012; 150:251-263.
6. Griewank KG, Scolyer RA, Thompson JF, et al. Genetic alterations and personalized medicine in melanoma: progress and future prospects. J Natl Cancer Inst 2014; 106:djt435.
7. Bartkova J, Lukas J, Guldberg P, et al. The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis. Cancer Res 1996; 56:5475-5483.
8. Fung C, Pupo GM, Scolyer RA, et al. p16(INK) (4a) deficiency promotes DNA hyper-replication and genetic instability in melanocytes. Pigment Cell Melanoma Res 2013; 26:236-246.
9. Nathanson KL, Martin AM, Wubbenhorst B, et al. Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436). Clin Cancer Res 2013; 19:4868-4878.
10. Pedace L, Cozzolino AM, Barboni L, et al. A novel variant in the 3'untranslated region of the CDK4 gene: interference with microRNA target sites and role in increased risk of cutaneous melanoma. Cancer Genet 2014.
11. Jonsson A, Tuominen R, Grafstrom E, et al. High frequency of p16(INK4A) promoter methylation in NRAS-mutated cutaneous melanoma. J Invest Dermatol 2010; 130:2809-2817.
12. Kwong LN, Costello JC, Liu H, et al. Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma. Nat Med 2012; 18:1503-1510.
13. Bennett DC. How to make a melanoma: what do we know of the primary clonal events? Pigment Cell Melanoma Res 2008; 21:27-38.
14. Puntervoll HE, Molven A, Akslen LA. Frequency of somatic BRAF mutations in melanocytic lesions from patients in a CDK4 melanoma family. Pigment Cell Melanoma Res 2014; 27:149-151.
15. Freedberg DE, Rigas SH, Russak J, et al. Frequent p16-independent inactivation of p14ARF in human melanoma. J Natl Cancer Inst 2008; 100:784-795.
16. Viros A, Sanchez-Laorden B, Pedersen M, et al. Ultraviolet radiation accelerates BRAF-driven melanomagenesis by targeting TP53. Nature 2014; 511:478-482.
17. Bruyere C, Meijer L. Targeting cyclin-dependent kinases in antineoplastic therapy. Curr Opin Cell Biol 2013; 25:772-779.
18. Zhang Y-X, Sicinska E, Czaplinski JT, et al. Antiproliferative effects of CDK4/6 inhibition in CDK4-amplified human liposarcoma in vitro and in vivo. Mol Cancer Ther 2014; 13:2184-2193.
19. Kim S, Loo A, Chopra R, et al. Abstract PR02: LEE011: An orally bioavailable, selective small molecule inhibitor of CDK4/6-Reactivating Rb in cancer. Mol Cancer Ther 2013; 12 (11 Supplement):R02-R.
20. Infante JR, Shapiro G, Witteveen P et al, editors. A phase I study of the singleagent CDK4/6 inhibitor LEE011 in pts with advanced solid tumors and lymphomas. J Clin Oncology (Meeting Abstracts) 2014; 32 (15 suppl):2528.
21. Sosman JA, Kittaneh M, MartijnPLolkema, et al. Aphase Ib/2 study ofLEE011 in combination with binimetinib (MEK162) in patients with advanced NRASmutant melanoma: Early encouraging clinical activity. J Clin Oncol 2014.
22. Schwartz GK, LoRusso PM, Dickson MA, et al. Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1). Brit J Cancer 2011; 104:1862-1868.
23. Davies MA. Targeted therapy for cutaneous melanoma: beyond BRAF. J Patient-Centered Res Rev 2014; 1:12-20.
24. Finn R, Crown J, Lang I, et al. Results of a randomized phase 2 study of PD 0332991, a cyclin-dependent kinase (CDK) 4/6 inhibitor, in combination with letrozole vs. letrozole alone for first-line treatment of ERþ /HER2-advanced breast cancer (BC). Cancer Res 2012; 72 (24 Suppl):S1-S6.
25. Gelbert LM, Cai S, Lin X, et al. Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent antitumor activities alone/in combination with gemcitabine. Invest New Drugs 2014; 32:825-837.
26. Shapiro G, Rosen LS, Tolcher AW, et al., editors. A first-in-human phase I study of the CDK4/6 inhibitor, LY2835219, for patients with advanced cancer. ASCO Meeting; Abstracts 2013; 31:2500.
27. Sheppard KE, McArthur GA. The cell-cycle regulator CDK4: an emerging therapeutic target in melanoma. Clin Cancer Res 2013; 19:5320-5328.
28. Young RJ, Waldeck K, Martin C, et al. Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines. Pigment Cell Melanoma Res 2014.
29. Desai BM, Villanueva J, Nguyen TT, et al. The antimelanoma activity of dinaciclib, a cyclin-dependent kinase inhibitor, is dependent on p53 signaling. PloS One 2013; 8:e59588.
30. Bhatia S, Emdad L, Das SK, et al. Non-BRAF targeted therapies for melanoma: protein kinase inhibitors in Phase II clinical trials. Expert Opin Investig Drugs 2014; 23:489-500.
31. Carlson BA, Dubay MM, Sausville EA, et al. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Cancer Res 1996; 56:2973-2978.
32. Smalley KS, Lioni M, Dalla Palma M, et al. Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas. Mol Cancer Ther 2008; 7:2876-2883.
33. Wang F-Z, Fei H-R, Cui Y-J, et al. The checkpoint 1 kinase inhibitor LY2603618 induces cell cycle arrest, DNA damage response and autophagy in cancer cells. Apoptosis 2014; 19:1389-1398.
34. Davies KD, Cable PL, Garrus JE, et al. Chk1 inhibition and Wee1 inhibition combine synergistically to impede cellular proliferation. Cancer Biol Ther 2011; 12:788-796.
35. Zabludoff SD, Deng C, Grondine MR, et al. AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies. Mol Cancer Ther 2008; 7:2955-2966.
36. McArthur GA, Raleigh J, Blasina A, et al., editors. Imaging with FLT-PET demonstrates that PF-477736, an inhibitor of CHK1 kinase, overcomes a cell cycle checkpoint induced by gemcitabine in PC-3 xenografts. J Clin Oncol (Meeting Abstracts) 2006; 24:3045.
37. Brooks K, Oakes V, Edwards B, et al. A potent CHK1 inhibitor is selectively cytotoxic in melanomas with high levels of replicative stress.Oncogene 2012; 32:788-796.
38. Blasina A, Hallin J, Chen E, et al. Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1. Mol Cancer Ther 2008; 7:2394-2404.
39. McNeely S, Beckmann R, Bence Lin AK. CHEK again: Revisiting the development of CHK1 inhibitors for cancer therapy. Pharmacol Ther 2014; 142:1-10.
40. Do K, Doroshow JH, Kummar S. Wee1 kinase as a target for cancer therapy. Cell Cycle 2013; 12:3159-3264.
41. Mahajan K, Mahajan NP. WEE1 tyrosine kinase, a novel epigenetic modifier. Trends Genet 2013; 29:394-402.
42. Bhattacharya A, Schmitz U, Wolkenhauer O, et al. Regulation of cell cycle checkpoint kinase WEE1 by miR-195 in malignant melanoma. Oncogene 2013; 32:3175-3183.
43. Gembarska A, Luciani F, Fedele C, et al. MDM4 is a key therapeutic target in cutaneous melanoma. Nat Med 2012; 18:1239-1247.
44. Thunell LK, Bivik C, Wäster P, et al. MDM2 SNP309 promoter polymorphism confers risk for hereditary melanoma. Melanoma Res 2014; 24:190-197.
45. Matin RN, Chikh A, Chong SL, et al. p63 is an alternative p53 repressor in melanoma that confers chemoresistance and a poor prognosis. J Exp Med 2013; 210:581-603.
46. Lu M, Breyssens H, Salter V, et al. Restoring p53 function in human melanoma cells by inhibiting MDM2 and cyclin B1/CDK1-phosphorylated nuclear iASPP. Cancer Cell 2013; 23:618-633.
47. Pant V, Lozano G. Dissecting the p53-Mdm2 feedback loop in vivo: uncoupling the role in p53 stability and activity. Oncotarget 2014; 5:1149.
48. Potu H, Peterson LF, Pal A, et al. Usp5 links suppression of p53 and FAS levels in melanoma to the BRAF pathway. Oncotarget 2014; 5:5559-5569.
49. Jochemsen AG. Reactivation of p53 as therapeutic intervention for malignant melanoma. Curr Opin Oncol 2014; 26:114-119.
50. Ji Z, Kumar R, Taylor M, et al. Vemurafenib synergizes with nutlin-3 to deplete survivin and suppresses melanoma viability and tumor growth. Clin Cancer Res 2013; 19:4383-4391.